Table 2.
Comparison of 2 groups of patients in intermediate group
| Parameters | Group A (n = 11) Serum bilirubin > 4 mg/dl Serum creatinine < 1 mg/dl |
Group B (n = 27) Serum bilirubin < 4 mg/dl Serum creatinine > 1 mg/dl |
P value |
|---|---|---|---|
| Age (median, range) | 49 (38-55) | 54 (38-72) | 0.02 |
| Sex | 0.46 | ||
| Male | 10 (90.9%) | 22 (81.5%) | |
| Female | 1 (9.1%) | 5 (18.5%) | |
| Aetiology of cirrhosis | 0.04 | ||
| Alcohol | 8 (72.7%) | 11 (40.7%) | |
| Hepatitis B/hepatitis C | 2 (18.2%) | 2 (7.4%) | |
| Cryptogenic | 1 (9.1%) | 14 (51.8%) | |
| Diabetes mellitus | 2 (18.2%) | 11 (40.7%) | 0.20 |
| Type of SBP | 0.19 | ||
| Community acquired | 7 (63.6%) | 11 (40.7%) | |
| Health care associated | 4 (36.4%) | 16 (59.3%) | |
| Cirrhosis-related complications | 0.57 | ||
| None | 5 (45.5%) | 15 (55.5%) | |
| One or more | 6 (54.5%) | 12 (44.5%) | |
| Baseline MELD | 0.43 | ||
| Median, range | 23 (19-28) | 23 (16-36) | |
| Serum sodium (meq/l) | 0.23 | ||
| Median, range | 130 (114-136) | 132 (118-147) | |
| Duration of albumin given in days | 0.67 | ||
| Median, range | 5 (3-7) | 5 (1-8) | |
| Antibiotic escalation | 2 (18.4%) | 14 (51.8%) | 0.06 |
| Adverse effects of albumin | 0.33 | ||
| Chest congestion | 2 (18.2%) | 2 (7.4%) | |
| Outcome | NA | ||
| Recovered | 11 (100%) | 16 (59.3%) | |
| Expired | 0 | 11 (40.7%) |